Resveratrol – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Resveratrol is a natural compound found in red wine, grape skins, and Japanese knotweed. It activates sirtuins and other longevity-associated pathways and has been the subject of intense longevity research. Oral bioavailability is poor, limiting clinical efficacy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

30/100

Well-studied polyphenol undermined by poor bioavailability and a partially-discredited SIRT1 narrative

Look, resveratrol had its moment. David Sinclair’s 2003 Cell paper on SIRT1 activation was genuinely exciting, and the follow-up 2006 Nature paper showing lifespan extension in obese mice turned this grape polyphenol into one of the most-hyped compounds in aging biology. The problem is that most of that story has since unraveled in ways that matter for bench work.

The SIRT1 activation mechanism (the whole foundation of the resveratrol narrative) turned out to be substrate-dependent. The original assay used an artificial fluorophore-tagged substrate, and when Pfizer’s group and others replicated with native peptide substrates, the activation was dramatically reduced or absent. SIRT1 activation is real in some substrate contexts but the claim that resveratrol is a general SIRT1 activator doesn’t hold up. That’s not a minor quibble; it’s the central claim. The compound still hits AMPK and NF-kB, and the antioxidant activity is real, but none of those targets are unique to resveratrol and none of them explain the original hype.

Bioavailability is the other killer. Oral resveratrol undergoes rapid phase-2 conjugation and first-pass metabolism, leaving plasma concentrations that are typically one to ten percent of what drives effects in cell culture. The human dose to hit effective tissue concentrations either isn’t achievable or requires doses that create their own tolerability issues. This isn’t new information; it’s been known since the early 2010s. It means that most clinical trials were essentially testing whether resveratrol works at sub-therapeutic concentrations. The answer, unsurprisingly, has been mostly no.

The clinical trial record reinforces this. The CALERIE-adjacent work, the trials in diabetic and metabolic patients, the cardiovascular studies: effect sizes are modest at best, null at worst. Resveratrol supplementation in otherwise healthy populations shows very little. There are some positive signals in specific subpopulations (older adults, high-fat-diet stress conditions) but nothing close to what the preclinical story implied, and the lifespan extension in mice failed to replicate in normally-fed animals.

What we don’t like about resveratrol as a research target right now: the field has genuinely moved on. If you’re interested in the sirtuin axis, NMN and NR have better pharmacokinetics and a more credible human signal. If you want a stilbenoid probe, pterostilbene has improved bioavailability and a tighter mechanistic story. If you want a polyphenol tool for NF-kB or antioxidant pathway work, there are cleaner options. Resveratrol still appears in bench protocols as a positive control for antioxidant assays and as a historical comparator in aging studies, and thats a legitimate use case. But it’s not where you’d anchor a research program in 2025. The hype-to-evidence ratio here is one of the worst in the longevity compound space, and that’s saying something.

Novelty: 22
Mechanism promise: 30
In-category differentiation: 20
Evidence quality: 52
Translational signal: 22
Research bench value: 40

Rationale Resveratrol scores low on novelty and differentiation because the flagship SIRT1 activation story is now known to be substrate-artifact-dependent, and the compound has been largely superseded by NMN/NR on the sirtuin axis and pterostilbene in the stilbenoid space; a large clinical trial base exists but mostly returns null results at achievable plasma concentrations, killing the translational score.

Stilbenoid polyphenol / sirtuin modulator

A trans-stilbenoid polyphenol from grapes and other plants, characterized by SIRT1 activation and pleiotropic anti-aging effects with disputed clinical efficacy.

Abstract

Resveratrol (trans-3,4′,5-trihydroxystilbene; CAS 501-36-0; molecular formula C14H12O3; molecular weight 228.25) is a stilbenoid polyphenol present in grapes, peanuts, berries, and several other plants. The compound has been extensively studied for anti-aging applications since David Sinclair’s group at Harvard demonstrated SIRT1 activation in 2003. Mechanism includes SIRT1 sirtuin activation (allosteric activator at certain peptide substrates; the activity is substrate-dependent), AMPK activation, anti-inflammatory effects through NF-kB inhibition, and direct antioxidant activity. Resveratrol extends lifespan in obese mice and in some short-lived model organisms but does not extend lifespan in normally fed mice; the lifespan-extending effect appears to be selective for high-fat-diet stress conditions. Bioavailability is poor (high first-pass metabolism); plasma resveratrol concentrations after oral administration are typically 1 to 10 percent of those that produce in vitro effects. Doses are typically 250 to 1500 mg per day. The clinical evidence base in humans is mixed; many endpoints show no effect at achievable plasma concentrations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-097Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.